Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H and H Receptors with Anti-inflammatory Potential

Overview

Journal Front Pharmacol

Date 2017 Nov 30

PMID 29184503

Citations 6

Authors

Michelle F Correa

Alefe J R Barbosa

Larissa B Teixeira

Diego A Duarte

Sarah C Simoes

Lucas T Parreiras-E-Silva

Aleksandro M Balbino

Richardt G Landgraf

Michel Bouvier

Claudio M Costa-Neto

Joao P S Fernandes

Affiliations

Soon will be listed here.

Abstract

The histamine receptors (HRs) are traditional G protein-coupled receptors of extensive therapeutic interest. Recently, HR and HR subtypes have been targeted in drug discovery projects for inflammation, asthma, pain, cancer, Parkinson's, and Alzheimer's diseases, which includes searches for dual acting HR/HR ligands. In the present work, nine 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazine (LINS01 series) molecules were synthesized and evaluated as HR and HR ligands. Our data show that the -allyl-substituted compound LINS01004 bears the highest affinity for HR (p 6.40), while the chlorinated compound LINS01007 has moderate affinity for HR (p 6.06). In addition, BRET assays to assess the functional activity of G1 coupling indicate that all compounds have no intrinsic activity and act as antagonists of these receptors. Drug-likeness assessment indicated these molecules are promising leads for further improvements. evaluation of compounds LINS01005 and LINS01007 in a mouse model of asthma showed a better anti-inflammatory activity of LINS01007 (3 g/kg) than the previously tested compound LINS01005. This is the first report with functional data of these compounds in HRs, and our results also show the potential of their applications as anti-inflammatory.

Citing Articles

Synthetic Protocols, Structural Activity Relationship, and Biological Activity of Piperazine and its Derivatives.

Faizan M, Kumar R, Mazumder A, Salahuddin , Kukreti N, Kumar A Med Chem. 2024; 20(8):753-780.

PMID: 38685782 DOI: 10.2174/0115734064304396240415110015.

In-vitro and in-silico antibacterial activity of Azadirachta indica (Neem), methanolic extract, and identification of Beta.d-Mannofuranoside as a promising antibacterial agent.

Altayb H, Yassin N, Hosawi S, Kazmi I BMC Plant Biol. 2022; 22(1):262.

PMID: 35610569 PMC: 9131563. DOI: 10.1186/s12870-022-03650-5.

Molecular Modeling of Histamine Receptors-Recent Advances in Drug Discovery.

Mehta P, Miszta P, Filipek S Molecules. 2021; 26(6).

PMID: 33810008 PMC: 8004658. DOI: 10.3390/molecules26061778.

Onion Bulb Extract Downregulates EGFR/ERK1/2/AKT Signaling Pathway and Synergizes With Steroids to Inhibit Allergic Inflammation.

El-Hashim A, Khajah M, Orabi K, Balakrishnan S, Sary H, Abdelali A Front Pharmacol. 2020; 11:551683.

PMID: 33123005 PMC: 7567342. DOI: 10.3389/fphar.2020.551683.

Ang-(1-7)/ MAS1 receptor axis inhibits allergic airway inflammation via blockade of Src-mediated EGFR transactivation in a murine model of asthma.

El-Hashim A, Khajah M, Babyson R, Renno W, Ezeamuzie C, Benter I PLoS One. 2019; 14(11):e0224163.

PMID: 31675376 PMC: 6824568. DOI: 10.1371/journal.pone.0224163.

References

Christopher F, Thangam E, Suresh M . A bioinformatics search for selective histamine h4 receptor antagonists through structure-based virtual screening strategies. Chem Biol Drug Des. 2012; 79(5):749-59. DOI: 10.1111/j.1747-0285.2012.01336.x. View

Santos G, Duarte D, Parreiras-E-Silva L, Teixeira F, Silva-Rocha R, Oliveira E . Comparative analyses of downstream signal transduction targets modulated after activation of the AT1 receptor by two β-arrestin-biased agonists. Front Pharmacol. 2015; 6:131. PMC: 4486767. DOI: 10.3389/fphar.2015.00131. View

Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S . Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem. 2000; 275(47):36781-6. DOI: 10.1074/jbc.M006480200. View

Reis R, Santos E, Pesquero J, Oliveira L, Schanstra J, Bascands J . Participation of transmembrane proline 82 in angiotensin II AT1 receptor signal transduction. Regul Pept. 2007; 140(1-2):32-6. DOI: 10.1016/j.regpep.2006.11.028. View

de Esch I, Thurmond R, Jongejan A, Leurs R . The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci. 2005; 26(9):462-9. DOI: 10.1016/j.tips.2005.07.002. View

Gales C, Rebois R, Hogue M, Trieu P, Breit A, Hebert T . Real-time monitoring of receptor and G-protein interactions in living cells. Nat Methods. 2005; 2(3):177-84. DOI: 10.1038/nmeth743. View

Verdonk M, Rees D . Group efficiency: a guideline for hits-to-leads chemistry. ChemMedChem. 2008; 3(8):1179-80. DOI: 10.1002/cmdc.200800132. View

Correa M, Varela M, Balbino A, Torrecilhas A, Landgraf R, Troncone L . 1-[(2,3-Dihydro-1-benzofuran-2-yl) methyl]piperazines as novel anti-inflammatory compounds: Synthesis and evaluation on H R/H R. Chem Biol Drug Des. 2017; 90(2):317-322. DOI: 10.1111/cbdd.12947. View

Lazewska D, Wiecek M, Ner J, Kaminska K, Kottke T, Schwed J . Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands. Eur J Med Chem. 2014; 83:534-46. DOI: 10.1016/j.ejmech.2014.06.032. View

10.

Medina V, Croci M, Crescenti E, Mohamad N, Sanchez-Jimenez F, Massari N . The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther. 2007; 7(1):28-35. DOI: 10.4161/cbt.7.1.5123. View

11.

Kottke T, Sander K, Weizel L, Schneider E, Seifert R, Stark H . Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands. Eur J Pharmacol. 2011; 654(3):200-8. DOI: 10.1016/j.ejphar.2010.12.033. View

12.

Shan L, Bossers K, Luchetti S, Balesar R, Lethbridge N, Chazot P . Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study. Neurobiol Aging. 2011; 33(7):1488.e1-13. DOI: 10.1016/j.neurobiolaging.2011.10.016. View

13.

Shan L, Bao A, Swaab D . The human histaminergic system in neuropsychiatric disorders. Trends Neurosci. 2015; 38(3):167-77. DOI: 10.1016/j.tins.2014.12.008. View

14.

Fernandes J, Pasqualoto K, Ferreira E, Brandt C . Molecular modeling and QSAR studies of a set of indole and benzimidazole derivatives as H₄ receptor antagonists. J Mol Model. 2010; 17(5):921-8. DOI: 10.1007/s00894-010-0779-4. View

15.

Correa M, Dos Santos Fernandes J . Histamine H4 receptor ligands: future applications and state of art. Chem Biol Drug Des. 2014; 85(4):461-80. DOI: 10.1111/cbdd.12431. View

16.

Leurs R, Bakker R, Timmerman H, de Esch I . The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005; 4(2):107-20. DOI: 10.1038/nrd1631. View

17.

Cheng Y, Prusoff W . Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22(23):3099-108. DOI: 10.1016/0006-2952(73)90196-2. View

18.

Veber D, Johnson S, Cheng H, Smith B, Ward K, Kopple K . Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45(12):2615-23. DOI: 10.1021/jm020017n. View

19.

Engelhardt H, de Esch I, Kuhn D, Smits R, Zuiderveld O, Dobler J . Detailed structure-activity relationship of indolecarboxamides as H4 receptor ligands. Eur J Med Chem. 2012; 54:660-8. DOI: 10.1016/j.ejmech.2012.06.016. View

20.

Passani M, Blandina P . Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci. 2011; 32(4):242-9. DOI: 10.1016/j.tips.2011.01.003. View